Vitrous Analysis in Proliferative Diabetic Retinopathy
Launched by ANDERS KVANTA · Nov 22, 2011
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
To analyse and compare vitreous proteins in patients undergoing pars plana vitrectomy for proliferative diabetic retinopathy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • proliferative diabetic retinopathy with vitreous hemorrhage
- Exclusion Criteria:
- • vitreous hemorrhage of other cause than proliferative diabetic retinopathy
- • previous vitrectomy
About Anders Kvanta
Anders Kvanta is a pioneering clinical trial sponsor dedicated to advancing medical research and innovation through rigorous study design and execution. Committed to enhancing patient care and treatment outcomes, the organization specializes in a wide range of therapeutic areas, employing cutting-edge methodologies and a patient-centered approach. With a focus on collaboration and transparency, Anders Kvanta partners with healthcare professionals and institutions to ensure the highest standards of quality and compliance in clinical trials. Their mission is to drive the development of safe and effective therapies that address unmet medical needs and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, Nonus, Sweden
Patients applied
Trial Officials
Anders Kvanta, PhD
Principal Investigator
St. Erik Eye Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials